Inhibition of LPS-induced C/EBPδ by trichostatin A has a positive effect on LPS-induced cyclooxygenase 2 expression in RAW264.7 cells

Journal of Cellular Biochemistry

Volumn 110, Issue 6, 2010, Pages 1430-1438

  Liu, Yi Wen ^a   Wang, Shao An ^b   Hsu, Tsung Yi ^b   Chen, Tsu An ^c   Chang, Wen Chang ^b,c   Hung, Jan Jong ^b,c  

^a NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

C EBP ; C EBP ; C EBP ; Cyclooxygenase 2; Trichostatin A

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; CCAAT ENHANCER BINDING PROTEIN DELTA; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TRANSCRIPTION FACTOR SP1; TRICHOSTATIN A;

ARTICLE; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; ONCOGENE C JUN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANIMALS; BLOTTING, WESTERN; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CCAAT-ENHANCER-BINDING PROTEIN-DELTA; CELL LINE; CYCLOOXYGENASE 2; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; LIPOPOLYSACCHARIDES; MACROPHAGES; NF-KAPPA B; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77955477207     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22682     Document Type: Article

References (44)

1. Belmonte N, Phillips BW, Massiera F, Villageois P, Wdziekonski B, Saint-Marc P, Nichols J, Aubert J, Saeki K, Yuo A, Narumiya S, Ailhaud G, Dani C. 2001. Activation of extracellular signal-regulated kinases and CREB/ATF-1 mediate the expression of CCAAT/enhancer binding proteins beta and -delta in preadipocytes. Mol Endocrinol 15:2037-2049.
2. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL. 2002. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc Natl Acad Sci USA 99:13926-13931.
3. Chen BK, Chang WC. 2000. Functional interaction between c-Jun and promoter factor Sp1 in epidermal growth factor-induced gene expression of human 12(S)-lipoxygenase. Proc Natl Acad Sci USA 97:10406-10411.
4. Chen LC, Chen BK, Chang JM, Chang WC. 2004. Essential role of c-Jun induction and coactivator p300 in epidermal growth factor-induced gene expression of cyclooxygenase-2 in human epidermoid carcinoma A431 cells. Biochim Biophys Acta 1683:38-48.
5. Chen BK, Huang CC, Chang WC, Chen YJ, Kikkawa U, Nakahama K, Morita I, Chang WC. 2007. PP2B-mediated dephosphorylation of c-Jun C terminus regulates phorbol ester-induced c-Jun/Sp1 interaction in A431 cells. Mol Biol Cell 18:1118-1127.
6. Chiang BT, Liu YW, Chen BK, Wang JM, Chang WC. 2006. Direct interaction of C/EBPdelta and Sp1 at the GC-enriched promoter region synergizes the IL-10 gene transcription in mouse macrophage. J Biomed Sci 13:621-635.
7. Cho MK, Cho YH, Lee GH, Kim SG. 2004. Induction of cyclooxygenase-2 by bovine type I collagen in macrophages via C/EBP and CREB activation by multiple cell signaling pathways. Biochem Pharmacol 67:2239-2250.
8. de Souza Pereira R. 2009. Selective cyclooxygenase-2 (COX-2) inhibitors used for preventing or regressing cancer. Recent Pat Anticancer Drug Discov 4:157-163.
9. Dempke W, Rie C, Grothey A, Schmoll HJ. 2001. Cyclooxygenase-2: A novel target for cancer chemotherapy? J Cancer Res Clin Oncol 127:411-417.
10. Evans JF, Kargman SL. 2004. Cancer and cyclooxygenase-2 (COX-2) inhibition. Curr Pharm Des 10:627-634.
11. Feng L, Xia Y, Garcia GE, Hwang D, Wilson CB. 1995. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide. J Clin Invest 95:1669-1675.
12. Gately S, Kerbel R. 2003. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 37:179-192.
13. Hoffmann U, Banas B, Kruger B, Pietrzyk M, Obed A, Segerer S, Kammerl M, Rummele P, Riegger GA, Kramer BK. 2006. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human renal allograft rejection- a prospective study. Transpl Int 19:203-212.
14. Hutt JA, O'Rourke JP, DeWille J. 2000. Signal transducer and activator of transcription 3 activates CCAAT enhancer-binding protein delta gene transcription in G0 growth-arrested mouse mammary epithelial cells and in involuting mouse mammary gland. J Biol Chem 275:29123-29131.
15. Hwang D, Jang BC, Yu G, Boudreau M. 1997. Expression of mitogen-inducible cyclooxygenase induced by lipopolysaccharide: Mediation through both mitogen-activated protein kinase and NF-kappaB signaling pathways in macrophages. Biochem Pharmacol 54:87-96.
16. Ishii Y, Kasukabe T, Honma Y. 2005. Induction of CCAAT/enhancer binding protein-delta by cytokinins, but not by retinoic acid, during granulocytic differentiation of human myeloid leukaemia cells. Br J Haematol 128:540-547.
17. Kapoor M, Shaw O, Appleton I. 2005. Possible anti-inflammatory role of COX-2-derived prostaglandins: Implications for inflammation research. Curr Opin Investig Drugs 6:461-466.
18. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. 1991. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266:12866-12872.
19. Kundu JK, Hwang DM, Lee JC, Chang EJ, Shin YK, Fujii H, Sun B, Surh YJ. 2009. Inhibitory effects of oligonol on phorbol ester-induced tumor promotion and COX-2 expression in mouse skin: NF-kappaB and C/EBP as potential targets. Cancer Lett 273:86-97.
20. Liaw YW, Liu YW, Chen BK, Chang WC. 1998. Induction of 12-lipoxygenase expression by phorbol 12-myristate 13-acetate in human epidermoid carcinoma A431 cells. Biochim Biophys Acta 1389:23-33.
21. Lindstrom TM, Mohan AR, Johnson MR, Bennett PR. 2008. Histone deacetylase inhibitors exert time-dependent effects on nuclear factor-kappaB but consistently suppress the expression of proinflammatory genes in human myometrial cells. Mol Pharmacol 74:109-121.
22. Liu YW, Chen CC, Wang JM, Chang WC, Huang YC, Chung SY, Chen BK, Hung JJ. 2007. Role of transcriptional factors Sp1, c-Rel, and c-Jun in LPS-induced C/EBPdelta gene expression of mouse macrophages. Cell Mol Life Sci 64:3282-3294.
23. Maihofner C, Charalambous MP, Bhambra U, Lightfoot T, Geisslinger G, Gooderham NJ. 2003. Expression of cyclooxygenase-2 parallels expression of interleukin-1beta, interleukin-6 and NF-kappaB in human colorectal cancer. Carcinogenesis 24:665-671.
24. Marks PA, Richon VM, Rifkind RA. 2000. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210-1216.
25. Marks PA, Richon VM, Breslow R, Rifkind RA. 2001. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13:477-483.
26. Murakami M, Kuwata H, Amakasu Y, Shimbara S, Nakatani Y, Atsumi G, Kudo I. 1997. Prostaglandin E2 amplifies cytosolic phospholipase A2- and cyclooxygenase-2-dependent delayed prostaglandin E2 generation in mouse osteoblastic cells. Enhancement by secretory phospholipase A2. J Biol Chem 272:19891-19897.
27. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, George DL. 1999. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13:2490-2501.
28. Newton R, Kuitert LM, Bergmann M, Adcock IM, Barnes PJ. 1997. Evidence for involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta. Biochem Biophys Res Commun 237:28-32.
29. Nikolakaki E, Coffer PJ, Hemelsoet R, Woodgett JR, Defize LH. 1993. Glycogen synthase kinase 3 phosphorylates Jun family members in vitro and negatively regulates their transactivating potential in intact cells. Oncogene 8:833-840.
30. Ramirez CJ, Haberbusch JM, Soprano DR, Soprano KJ. 2005. Retinoic acid induced repression of AP-1 activity is mediated by protein phosphatase 2A in ovarian carcinoma cells. J Cell Biochem 96:170-182.
31. Ramji DP, Foka P. 2002. CCAAT/enhancer-binding proteins: Structure, function and regulation. Biochem J 365:561-575.
32. Reddy ST, Tiano HF, Langenbach R, Morham SG, Herschman HR. 1999. Genetic evidence for distinct roles of COX-1 and COX-2 in the immediate and delayed phases of prostaglandin synthesis in mast cells. Biochem Biophys Res Commun 265:205-210.
33. Sarkar FH, Adsule S, Li Y, Padhye S. 2007. Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem 7:599-608.
34. Stratton MS, Alberts DS. 2002. Current application of selective COX-2 inhibitors in cancer prevention and treatment. Oncology (Williston Park) 16:37-51.
35. Suske G. 1999. The Sp-family of transcription factors. Gene 238:291-300.
36. Taddei A, Roche D, Bickmore WA, Almouzni G. 2005. The effects of histone deacetylase inhibitors on heterochromatin: Implications for anticancer therapy? EMBO Rep 6:520-524.
37. Tanabe T, Tohnai N. 2002. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 68-69:95-114.
38. Toomey DP, Murphy JF, Conlon KC. 2009. COX-2, VEGF and tumour angiogenesis. Surgeon 7:174-180.
39. Usami M, Kishimoto K, Ohata A, Miyoshi M, Aoyama M, Fueda Y, Kotani J. 2008. Butyrate and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutr Res 28:321-328.
40. Vanhaecke T, Papeleu P, Elaut G, Rogiers V. 2004. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: Toxicological point of view. Curr Med Chem 11:1629-1643.
41. Wang YN, Chang WC. 2003. Induction of disease-associated keratin 16 gene expression by epidermal growth factor is regulated through cooperation of transcription factors Sp1 and c-Jun. J Biol Chem 278:45848-45857.
42. Woo KJ, Lim JH, Suh SI, Kwon YK, Shin SW, Kim SC, Choi YH, Park JW, Kwon TK. 2006. Differential inhibitory effects of baicalein and baicalin on LPS-induced cyclooxygenase-2 expression through inhibition of C/EBPbeta DNA-binding activity. Immunobiology 211:359-368.
43. Xie W, Herschman HR. 1996. Transcriptional regulation of prostaglandin synthase 2 gene expression by platelet-derived growth factor and serum. J Biol Chem 271:31742-31748.
44. Yamaguchi K, Lantowski A, Dannenberg AJ, Subbaramaiah K. 2005. Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2. J Biol Chem 280:32569-32577.